New Hope, PA, United States of America

Michael Reuman

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Mind of Michael Reuman

Introduction

Michael Reuman is a prominent inventor based in New Hope, Pennsylvania, known for his innovative contributions to the field of pharmaceuticals. With a remarkable patent to his name, he exemplifies the spirit of innovation that drives advancements in medical science.

Latest Patents

Reuman holds a notable patent titled "Fused cyclopentyl antagonists of CCR2." This invention encompasses processes for preparing compounds defined by specific structural formulas, which are detailed in the patent specification. His work in this area represents a significant step forward in understanding and potentially treating conditions related to the CCR2 receptor.

Career Highlights

Throughout his career, Michael Reuman has worked with Janssen Pharmaceutica NV, a leading global pharmaceutical company. His expertise and dedication have contributed to the organization’s ongoing mission of advancing healthcare through innovative drug development.

Collaborations

During his tenure at Janssen Pharmaceutica NV, Reuman has collaborated with esteemed colleagues, including Shawn T. Branum and Ronald K. Russell. These partnerships exemplify the importance of teamwork in the realm of scientific research and invention, further enhancing the potential for groundbreaking discoveries.

Conclusion

Michael Reuman stands out as a pioneering inventor whose work continues to influence the field of pharmaceuticals. His patent on fused cyclopentyl antagonists illustrates his commitment to innovation and underscores the vital role that inventors play in advancing medical science and improving patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…